• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Mitoxantrone hydrochloride liposome combined with cytarabine for treating pediatric acute myeloid leukemia with RUNX1∷MTG16 fusion gene: a case report and literature review].盐酸米托蒽醌脂质体联合阿糖胞苷治疗伴RUNX1∷MTG16融合基因的儿童急性髓系白血病：1例报告及文献复习
Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 14;45(12):1134-1137. doi: 10.3760/cma.j.cn121090-20240805-00289.
2
[Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].7例伴有DEK-NUP214融合基因的儿童急性髓系白血病分析
Zhonghua Er Ke Za Zhi. 2023 Apr 2;61(4):357-362. doi: 10.3760/cma.j.cn112140-20220704-00619.
3
RUNX1-MTG16 fusion gene in acute myeloblastic leukemia with t(16;21)(q24;q22): case report and review of the literature.伴有t(16;21)(q24;q22)的急性髓系白血病中的RUNX1-MTG16融合基因：病例报告及文献复习
Cancer Genet Cytogenet. 2008 Aug;185(1):47-50. doi: 10.1016/j.cancergencyto.2008.04.011.
4
Complex t(2;21;8)(p12;q22;q22): a variant t(8;21) in a patient with acute myeloid leukemia (AML-M2).复杂的t(2;21;8)(p12;q22;q22)：一名急性髓系白血病（AML-M2）患者中的一种变异型t(8;21) 。
Cancer Genet Cytogenet. 2009 Jan 15;188(2):95-8. doi: 10.1016/j.cancergencyto.2008.08.007.
5
Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).高三尖杉酯碱、阿克拉霉素和阿糖胞苷（HAA）方案作为诱导治疗的首个疗程，对伴有t（8；21）的急性髓系白血病非常有效。
Leuk Res. 2016 May;44:40-4. doi: 10.1016/j.leukres.2016.02.012. Epub 2016 Feb 27.
6
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.急性髓系白血病的双重诱导策略：高剂量阿糖胞苷联合米托蒽醌替代标准剂量阿糖胞苷联合柔红霉素及6-硫鸟嘌呤的疗效：德国急性髓系白血病协作组的一项随机试验
Blood. 1999 Jun 15;93(12):4116-24.
7
Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.伴有 t(16;21)(q24;q22)/RUNX1-RUNX1T3 的髓系肿瘤类似于伴有 RUNX1-RUNX1T1 的急性髓系白血病。
Ann Hematol. 2018 Oct;97(10):1775-1783. doi: 10.1007/s00277-018-3389-3. Epub 2018 Jun 5.
8
Childhood acute myeloid leukemia with bone marrow eosinophilia caused by t(16;21)(q24;q22).伴有骨髓嗜酸性粒细胞增多的儿童急性髓系白血病，由 t(16;21)(q24;q22)引起。
Int J Hematol. 2012 May;95(5):577-80. doi: 10.1007/s12185-012-1044-7. Epub 2012 Mar 9.
9
Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1.治疗三种儿科 AML 共表达 NUP98-NSD1、FLT3-ITD 和 WT1。
BMC Pediatr. 2024 Jul 27;24(1):483. doi: 10.1186/s12887-024-04954-1.
10
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.Q-HAM 研究：一项多中心、 upfront 随机化的 II 期临床试验，评估了 quizartinib 联合高剂量阿糖胞苷和米托蒽醌在伴有 FLT3-ITD 的复发/难治性 AML 患者中的疗效。
Trials. 2023 Sep 15;24(1):591. doi: 10.1186/s13063-023-07421-x.

本文引用的文献

1
[Clinical Analysis of Mitoxantrone Liposome in the Treatment of Children with High-Risk Acute Myeloid Leukemia].米托蒽醌脂质体治疗儿童高危急性髓系白血病的临床分析
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):365-369. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.006.
2
Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.米托蒽醌与脂质体柔红霉素在基于残留病流式细胞术检测的风险分层诱导小儿急性髓系白血病中的比较。
J Clin Oncol. 2024 Jun 20;42(18):2174-2185. doi: 10.1200/JCO.23.01841. Epub 2024 Apr 11.
3
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.急性髓系白血病完全缓解（CR）伴部分血液学恢复（CRh）的临床评估：来自七个队列的7235例患者报告
Leukemia. 2024 Feb;38(2):389-392. doi: 10.1038/s41375-024-02143-8. Epub 2024 Jan 23.
4
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.伴有核心结合因子急性髓系白血病和 FLT3-ITD 的患者的特征和结局：一项国际协作研究的结果。
Haematologica. 2022 Apr 1;107(4):836-843. doi: 10.3324/haematol.2021.278645.
5
U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.U2AF1 突变通过激活 FOXO3a 促进自噬通量从而促进骨髓增生异常综合征的肿瘤发生。
Cell Death Dis. 2021 Jun 28;12(7):655. doi: 10.1038/s41419-021-03573-3.
6
Design of liposomes as drug delivery system for therapeutic applications.脂质体作为治疗应用的药物传递系统的设计。
Int J Pharm. 2021 May 15;601:120571. doi: 10.1016/j.ijpharm.2021.120571. Epub 2021 Apr 2.
7
Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.剂量比对米托蒽醌和柔红霉素在急性髓系白血病中的影响：系统评价和随机对照试验的荟萃分析。
Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e10-e20. doi: 10.1016/j.clml.2020.08.001. Epub 2020 Aug 6.
8
Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.急性髓系白血病患者 SRSF2、U2AF1 和 SF3B1 突变的临床表现和差异剪接。
Leukemia. 2020 Oct;34(10):2621-2634. doi: 10.1038/s41375-020-0839-4. Epub 2020 May 1.
9
[The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy].[二代测序检测的克隆基因突变在接受强化巩固治疗的RUNX1-RUNX1T1阳性急性髓系白血病患者中的预后价值]
Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 14;41(3):210-215. doi: 10.3760/cma.j.issn.0253-2727.2020.03.005.
10
[Therapy-related acute myeloid leukemia with t(9;22)(q34;q11) and t(16;21)(q24;q22) double translocation: a case report and literature review].伴t(9;22)(q34;q11)和t(16;21)(q24;q22)双易位的治疗相关急性髓系白血病：1例报告并文献复习
Zhonghua Xue Ye Xue Za Zhi. 2019 Nov 14;40(11):956-958. doi: 10.3760/cma.j.issn.0253-2727.2019.11.014.

盐酸米托蒽醌脂质体联合阿糖胞苷治疗伴RUNX1∷MTG16融合基因的儿童急性髓系白血病：1例报告及文献复习

[Mitoxantrone hydrochloride liposome combined with cytarabine for treating pediatric acute myeloid leukemia with RUNX1∷MTG16 fusion gene: a case report and literature review].

作者信息

Lin S, Qi B Q, Liu L P, Xiao J G, Yang W Y, Zhu X F, Chen X J

机构信息

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 14;45(12):1134-1137. doi: 10.3760/cma.j.cn121090-20240805-00289.

DOI:10.3760/cma.j.cn121090-20240805-00289
PMID:39765356
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11886699/
Abstract

This case report presents a patient with pediatric acute myeloid leukemia (AML) with RUNX1∷MTG16, admitted to the Blood Disease Hospital of the Chinese Academy of Medical Sciences in October 2023. He was 13 years old, with a chief complaint of fatigue for 20 days. Bone marrow smear revealed 17.0% blasts, the karyotype was 46,XY,t (16; 21) (q24; q22), molecular biology demonstrated RUNX1∷MTG16 fusion gene, combined with FLT3-ITD mutation. The child was diagnosed with AML (with RUNX1 ∷ MTG16). Complete remission was achieved after chemotherapy induction. The induction therapy regimen was mitoxantrone hydrochloride liposomes combined with cytarabine (MA). The RUNX1 ∷ MTG16 and FLT3-ITD were negative after another MA treatment course. However, the RUNX1 ∷ MTG16 and FLT3-ITD were turning positive during the following intensive treatment, and he then successfully underwent matched sibling donor umbilical cord blood transplantation.

摘要

本病例报告介绍了一名患有RUNX1∷MTG16的小儿急性髓系白血病（AML）患者，于2023年10月入住中国医学科学院血液病医院。患者为13岁男性，主要诉求为乏力20天。骨髓涂片显示原始细胞占17.0%，核型为46,XY,t(16;21)(q24;q22)，分子生物学检测显示RUNX1∷MTG16融合基因，并伴有FLT3-ITD突变。该患儿被诊断为AML（伴RUNX1∷MTG16）。化疗诱导后达到完全缓解。诱导治疗方案为盐酸米托蒽醌脂质体联合阿糖胞苷（MA）。在另一个MA疗程后，RUNX1∷MTG16和FLT3-ITD均为阴性。然而，在随后的强化治疗期间，RUNX1∷MTG16和FLT3-ITD转为阳性，随后他成功接受了同胞全相合供者脐血移植。